Abstract Library

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4654 Usefulness of soluble tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors R2 and R3 in progression assessment of gastroenteropancreatic neuroendocrine neoplasms – A preliminary study

Introduction: TRAIL is a member of TNF family and appears in membrane and soluble (s) forms. It acts either triggering (R1 and R2) or blocking (R3 and R4) apoptosis. TRAIL targeted therapy is widely studied and known as potentially effective in number of neoplasms.

Conference:

Presenting Author: Kaczmarska-Turek D

Authors: Kaczmarska-Turek D, Radziszewski M, Matałowski M, Liszcz A, Bartoszewicz Z,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, tumour necrosis factor-related apoptosis-inducing ligand, tumour progression, PRRT, TRAIL, GEP-NEN,

#4423 Exploring decorin in plasma-derived small extracellular vesicles (sEVs) as a potential diagnostic biomarker for pancreatic neuroendocrine tumours

Introduction: Pancreatic Neuroendocrine tumours (PanNETs), the most common site for GEP‑NENs in Asian countries, particularly India, have shown increasing incidence. Due to a lack of specific biomarkers, often detected at advanced stages. So, this study utilised PanNET tissue proteomics for cancer biomarker discovery and explored the impact of small extracellular cellular vesicles (sEVs) in PanNET growth and metastasis, as they reflect the molecular profile of their tissue of origin.

Conference:

Presenting Author:

Authors: Gorai P, As S, Naik M, Kumar S, Pal S,

Keywords: Decorin, small extracellular vesicles, Pancreatic Neuroendocrine Tumour, Proteomics, circulating biomarker,

#4406 Fluorescence labelled plasma derived small extracellular vesicle as biomarkers in metastatic pancreatic neuroendocrine tumour patients

Introduction: Pancreatic neuroendocrine tumours (PanNET) are rare with increased annual incidence rate 1/lac. There are no specific biomarkers, diagnostic and prognostic tests available for PanNET. The small extracellular vesicles (sEV) play a key role in tumour growth and metastasis and can be a potential biomarker for metastasis of PanNET.

Conference:

Presenting Author:

Authors: As S, Gorai P, Naik M, Kumar R, Kumar S,

Keywords: Metastasis, Pancreatic neuroendocrine tumour, Small extracellular vesicles, Fluorescence, Nanoparticle tracking analysis,

#4337 Differences in plasma concentrations of selected growth factors in endocrine neoplasms – A pilot study

Introduction: Serum levels of growth factors associated with endocrine tumours may be potentially useful in detecting their recurrence.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Kurzynska A, Morawiec-Slawek K, Stefanska A, Kolasa M,

Keywords: growth factor, endocrine tumour, TNF-α, Fascin, recurrence risk,